Biosimulation Market Worth $ 2.88 Billion By 2022 – Exclusive Report By Marketsandmarkets™

By Author: Prachee
Total Articles: 39
Comment this article

Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022", is expected to reach USD 2.88 Billion by 2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%. The growth of this market is majorly driven by factors such as the increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=838

Browse in-depth TOC on "Biosimulation Market”

187 – Tables

28 – Figures

180 – Pages

Biosimulation software expected to dominate the market in 2017.

Based on product and service, the biosimulation market is segmented into software and services. In 2017, the biosimulation software segment ...
... is expected to account for the largest share of the biosimulation market. The high growth of this segment is attributed to the growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.

Based on end user, the pharmaceutical and biotechnology companies segment is projected to grow at the highest CAGR during the forecast period.

Based on end user, the biosimulation market is segmented into research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users (consulting firms, defense research and development organizations, nutraceutical companies, and food and agricultural companies). The pharmaceutical and biotechnology companies segment is expected to register the highest CAGR during the forecast period. Increased R&D budgets of pharmaceutical and biotechnology companies and increasing adoption of inorganic growth strategies by different biosimulation service providers are likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology industry.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=838

North America to dominate the biosimulation market

In 2017, North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to factors such as growth in the biotechnology and pharmaceutical industry, a large number of ongoing drug development processes, increased use of personalized medicine, and increasing R&D expenditure by pharmaceutical and biotechnology companies

Key Player

The biosimulation market is highly competitive with the presence of several small and big players. Some of the players in the biosimulation market include Certara (US), Simulation Plus (US), Dassault Systèmes (France), Schrödinger (US), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata (Switzerland).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=838

Browse Adjacent Market: 3D Bioprinting Market Research Reports & Consulting

Related Reports:

laboratory-equipment-service-market by Type (Repair & Maintenance, Calibration, Validation), Contract (Standard, Custom), Equipment (Analytical, Equipment, General, Support), Service Provider (OEM), and End User (Pharmaceutical) - Global Forecast to 2024

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biosimulation-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/biosimulation.asp